SCOL.ST Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (13 May 2024 @ 11:24):

Stats
Today's Volume	138 249
Average Volume	106 385
Market Cap	56.58M
EPS	SEK0 ( 2024-02-27 )
Next earnings date	( SEK0 ) 2024-05-29
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-0.920
ATR14	SEK0.0230 (1.65%)

Scandion Oncology A/S Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Scandion Oncology A/S Financials

Annual	2023
Revenue:	SEK0
Gross Profit:	SEK0 (0.00 %)
EPS:	SEK-0.960

FY	2023
Revenue:	SEK0
Gross Profit:	SEK0 (0.00 %)
EPS:	SEK-0.960

FY	2022
Revenue:	SEK0
Gross Profit:	SEK0 (0.00 %)
EPS:	SEK-1.790

FY	2021
Revenue:	SEK0.00
Gross Profit:	SEK0.00 (0.00 %)
EPS:	SEK-1.610

Financial Reports:

No articles found.

Scandion Oncology A/S

Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of chemotherapy resistance. Its lead product candidate includes the SCO-101, an oral compound that is in clinical Phase Ib and Phase II studies in cancer patients. The company's other product candidate is SCO-201, which is in preclinical trial for the treatment of solid tumors. Scandion Oncology A/S was founded in 2017 and is headquartered in Copenhagen, Denmark.